Literature DB >> 9209656

Integration of Epstein-Barr virus in Burkitt's lymphoma cells leads to a region of enhanced chromosome instability.

A Jox1, C Rohen, G Belge, S Bartnitzke, M Pawlita, V Diehl, J Bullerdiek, J Wolf.   

Abstract

BACKGROUND: Several lymphomas are associated with Epstein-Barr virus (EBV) infection. However EBV is not detectable in 100% of cases using standard staining techniques. It still remains an open question whether in these EBV-negative cases EBV has never infected the cell, whether it has infected the cell and escapes conventional screening methods, or whether it has been lost again after initial infection.
MATERIALS AND METHODS: The physical status of EBV in the Burkitt's lymphoma cell line BL60-P7 as well as in three somatic cell hybrids between BL60-P7 and its autologous EBV-immortalized lymphoblastoid cell line IARC 277 was analyzed using conventional cytogenetics, Southern blotting, and fluorescence in situ hybridization (FISH).
RESULTS: Integration of EBV into the host genome of the lymphoma cell line BL60-P7 leads to an achromatic gap which causes a 'vulnerable site'. In hybrid cells, loss of integrated EBV, together with an adjacent chromosomal fragment, occurs during long-term cultivation. The integrated EBV genome, including genes encoding for LMP and EBER, is partly deleted.
CONCLUSION: We assume that integration of EBV into the host cell genome could be a more common event in lymphoma cells. Partially deleted EBV might escape standard detection assays. The integration might constitute a chromosomal region prone to break events akin to the phenomenon of fragile sites, leading to the loss of viral DNA as well as chromosomal DNA. This observation makes it tempting to speculate that under certain conditions EBV can act in lymphomagenesis by a so-called hit-and-run mechanism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209656

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  13 in total

1.  Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells : no evidence for the persistence of integrated viral fragments inLatent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease.

Authors:  A Staratschek-Jox; S Kotkowski; G Belge; T Rüdiger; J Bullerdiek; V Diehl; J Wolf
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  Development of lymphoma from the donor of haploidentical stem cell transplantation: A case report.

Authors:  Linna Xie; Fang Zhou
Journal:  Mol Clin Oncol       Date:  2017-09-19

Review 3.  Current Progress in EBV-Associated B-Cell Lymphomas.

Authors:  Yonggang Pei; Alexandria E Lewis; Erle S Robertson
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

4.  In depth comparison of an individual's DNA and its lymphoblastoid cell line using whole genome sequencing.

Authors:  Dorothee Nickles; Lohith Madireddy; Shan Yang; Pouya Khankhanian; Steve Lincoln; Stephen L Hauser; Jorge R Oksenberg; Sergio E Baranzini
Journal:  BMC Genomics       Date:  2012-09-14       Impact factor: 3.969

Review 5.  Epstein-Barr virus and Hodgkin's disease.

Authors:  L M Weiss
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

Review 6.  Viral carcinogenesis: factors inducing DNA damage and virus integration.

Authors:  Yan Chen; Vonetta Williams; Maria Filippova; Valery Filippov; Penelope Duerksen-Hughes
Journal:  Cancers (Basel)       Date:  2014-10-22       Impact factor: 6.639

7.  Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies.

Authors:  Miao Xu; Wei-Long Zhang; Qing Zhu; Shanshan Zhang; You-Yuan Yao; Tong Xiang; Qi-Sheng Feng; Zhe Zhang; Rou-Jun Peng; Wei-Hua Jia; Gui-Ping He; Lin Feng; Zhao-Lei Zeng; Bing Luo; Rui-Hua Xu; Mu-Sheng Zeng; Wei-Li Zhao; Sai-Juan Chen; Yi-Xin Zeng; Yuchen Jiao
Journal:  Theranostics       Date:  2019-01-30       Impact factor: 11.556

Review 8.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14

9.  Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2012-11-22

10.  Genome-wide Analysis of Epstein-Barr Virus (EBV) Integration and Strain in C666-1 and Raji Cells.

Authors:  Kai Xiao; Zhengyuan Yu; Xiayu Li; Xiaoling Li; Ke Tang; Chaofeng Tu; Peng Qi; Qianjin Liao; Pan Chen; Zhaoyang Zeng; Guiyuan Li; Wei Xiong
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.